iser 2012 berlin

1. Emiliano S. Lopez , Oscar J. Croxatto, Juan E. Gallo
Facultad de Ciencias Biomédicas, Universidad Austral; Oftalmologia, Hospital Universitario
Austral , Pilar- Buenos Aires ; Patologia Ocular, Fundación Oftalmológica Argentina "Jorge
Malbran", Buenos Aires, Argentina.

2. SURAMAB
- EP 2186529; granted 28 March 2012.
- US Patent pending.

3. Suramin
Bevacizumab

4.  We have previously shown that Suramab,
a novel pharmaceutical compound, has
antiangiogenic properties.
 ES Lopez , MM Rizzo, JO Croxatto , G Mazzolini , JE Gallo.
Suramab, a novel antiangiogenic agent, reduces tumor
growth and corneal neovascularization. Cancer Chemother
Pharmacol 2011; 67:723–728

5.  To analyse the role of VEGF, bFGF, LYVE-1
and P2X2 in the antiangiogenic mechanism of
suramab in a rabbit model of corneal
neovascularization.

6. 9 Rabbits 9 Rabbits 9 Rabbits
Photographs d9 d15 d21
d35

7. Anesthesia filter disc (7mm) Na(OH) 1M (1min) Wash SB
-L. David Ormerod. Standard Models of Corneal Injury Using Alcali-Inmersed filter discs. Investigative Ophthalmology & Visual
Science, Vol. 30, Nº. 10, October 1989.

8. CLINICAL FOLLOW-UP
Suramab Bevacizumab Control
DAY 9
DAY15
DAY 35

9.  Rabbits treated with Suramab
showed a lower neovessel index
than that seen in controls at 35
days (T student, p<0.0001).
 Suramab had a greater
antiangiogenic effect than
that seen in animals treated
with Bevacizumab (T
student, p<0.02).

10. CONTROL TREATED GROUPS
Suramab Control

11. Control Suramab Bevacizumab
S C B
VEGF 42kDa
ACTIN 43kDa

12. SURAMAB BEVACIZUMAB CONTROL
S C B
40 kD
LYVE-1
ACTIN 43 kD

13. Control Bevacizumab Suramab
C S B
50kD
P2X2
43kD
ACTIN

14. Western Blot
B C S
19 kD
bFGF
B C S
43 kD
ACTIN

15. CONCLUSIONS
- Suramab has a strong antiangiogenic
effect.
- VEGF, P2X2, LYVE-1 and bFGF are
involved in the antiangiogenic
mechanism.

16. CONTROL
Control Suramab+P Suramab
Clinical evolution
50
40
Area of NV (%)
Control 38.22 35.3 30 29 31 22 30
Suramab 19.4 3 6 5 8 9 20
10
S+P 5 0 1 2 1 1
0
S
P
ol
S+
tr
on
C
Groups ( 14 days postinjury)

17. CONCLUSIONS
- Drug delivery systems are being
currently developed to improve
suramab ´s performance in the
treatment of corneal and retinal
neovascularization.

18. THANK YOU!

20. 3 Conejos 3 Conejos 3 Conejos

21. Evolución clínica
Control Suramina EV Bevacizumab
DIA 9
DIA 35

22. INV promedios
Días post-lesión

23. P407/P188/NaCl/Chitosan (24/20/0.9/0.5 % w/w)
1,00E+04
1,00E+03
1,00E+02
1,00E+01
P
V
o
a
y
c
s
)
(
t
.
i
Poloxamers
Poloxamers-Hialuronato
Poloxamers-Chitosan
1,00E+00
0 5 10 15 20 25 30 35 40 45
1,00E-01
Temperatura °C
Polímero T gel T gel II Viscosidad a
P407/P188 Vehículo % (w/w) I (°C) (°C) 35°C (Pas)
NaCl 0.9% 26,4 27,9 14100
(24/20)
NaCl 0.9% 24,8 26,4 17800
%w/w
0,5 (Chitosan)
NaCl 0.9% 0,25 (Hialuronato 25,3 27,9 14100
de Sodio)
Dr. Santiago Palma, Daniela Quinteros. Universidad Nacional de Cordoba